Close Menu

NEW YORK – Aileron Therapeutics said on Monday that it has enrolled the first patient in its Phase IB/II trial evaluating whether pretreating TP53-mutated small-cell lung cancer patients with its investigational drug ALRN-6924 can reduce the chemotherapy-induced toxicities associated with topotecan.

Prior to enrollment, patients must have either recurred or relapsed on chemotherapy or immunochemotherapy and have their TP53 mutation status confirmed by next-generation sequencing.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
16

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.